TetraLogic Pharmaceuticals Corporation

TLOGOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$979

P/E Ratio—

52W High$0.001

52W Low$0.00004

Avg Volume178

Open$0.00

Beta4.06

Free Cash Flow Financials Revenue

TetraLogic Pharmaceuticals Corporation (TLOG) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

TLOG · free cash flow · updated Jun 9, 2026

Core FCF metrics

TLOG · FCF · TTM · margin & CAGR

Free cash flow was −$35.0M for FY2015 (fiscal year ending 2015-12-31), down 6.3% year-over-year

FY2015 Free Cash Flow−$35.0M▼ -6.3% YoY

Trailing 12M (TTM)−$23.9Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

TLOG · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2015Latest−$34.9M(0M)−$35.0M▼ 6.3%—

FY2014−$32.4M(1M)−$32.9M▼ 156.2%—

FY2013−$12.8M(0M)−$12.8M▲ +19.6%—

FY2012−$15.9M(0M)−$16.0M▲ +8.0%—

FY2011−$17.3M(0M)−$17.3M——

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

TLOG · P/FCF · FCF yield · FCF per share

TetraLogic Pharmaceuticals Corporation (TLOG) reported negative free cash flow of −$0.03B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2015 · 2015-12-31

Cash flow statement summary

TLOG · cash flow statement · operating / investing / financing

For FY2015, TetraLogic Pharmaceuticals Corporation generated −$34.9M in operating cash flow and spent 0M in capital expenditures, yielding −$35.0M in free cash flow.

Operating Activities

−$34.9M

Cash from core business operations

2015-12-31

Investing Activities

+$35.4M

CapEx, acquisitions & investments

2015-12-31

Financing Activities

+$1.8M

Buybacks, dividends & debt

2015-12-31

FCF FormulaOperating CF (−$34.9M) − |CapEx| (0M) = FCF (−$35.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

TLOG vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

TetraLogic Pharmaceuticals CorporationYOU

TLOG

−$35.0M-6.3%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

TetraLogic Pharmaceuticals Corporation (TLOG) reported free cash flow of −$35.0M for FY2015 (fiscal year ending 2015-12-31), down 6.3% year-over-year.

TetraLogic Pharmaceuticals Corporation has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 5 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

TLOG free cash flow · 8 questions

TetraLogic Pharmaceuticals Corporation free cash flow was −$35.0M for FY2015, down 6.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$23.9M.

TLOG free cash flowTLOG FCFTLOG FCF 2015TLOG free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · TetraLogic Pharmaceuticals Corporation · TetraLogic Pharmaceuticals Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026